Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
369.96
-0.95 (-0.26%)
At close: Jan 13, 2026, 4:00 PM EST
370.00
+0.04 (0.01%)
After-hours: Jan 13, 2026, 6:59 PM EST
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 26 analysts that cover Alnylam Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $488.08, which forecasts a 31.93% increase in the stock price over the next year. The lowest target is $351 and the highest is $583.
Price Target: $488.08 (+31.93%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 14 | 13 | 13 | 13 | 13 |
| Buy | 10 | 11 | 11 | 10 | 10 | 9 |
| Hold | 4 | 4 | 3 | 4 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 27 | 29 | 27 | 27 | 28 | 27 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $530 → $529 | Strong Buy | Maintains | $530 → $529 | +42.99% | Jan 12, 2026 |
| Needham | Needham | Strong Buy Maintains $520 → $529 | Strong Buy | Maintains | $520 → $529 | +42.99% | Jan 12, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $535 → $530 | Strong Buy | Maintains | $535 → $530 | +43.26% | Jan 8, 2026 |
| Leerink Partners | Leerink Partners | Hold Maintains $370 → $351 | Hold | Maintains | $370 → $351 | -5.12% | Dec 15, 2025 |
| Stifel | Stifel | Strong Buy Maintains $495 → $508 | Strong Buy | Maintains | $495 → $508 | +37.31% | Dec 11, 2025 |
Financial Forecast
Revenue This Year
3.82B
from 2.25B
Increased by 70.04%
Revenue Next Year
5.47B
from 3.82B
Increased by 43.08%
EPS This Year
1.87
from -2.18
EPS Next Year
6.96
from 1.87
Increased by 271.69%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 4.4B | 6.4B | ||||
| Avg | 3.8B | 5.5B | ||||
| Low | 3.2B | 4.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 97.4% | 68.0% | ||||
| Avg | 70.0% | 43.1% | ||||
| Low | 44.5% | 21.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.64 | 11.51 | ||||
| Avg | 1.87 | 6.96 | ||||
| Low | -0.19 | 1.93 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 514.7% | ||||
| Avg | - | 271.7% | ||||
| Low | - | 3.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.